The Conversation (0)
MMRGlobal Inc (OTCQB:MMRF) announced that the Australian Patent Office has awarded the company a Notice of Allowance for its anti-CD20 monoclonal antibody assets under the title, “Antibodies and Methods for Making and Using Them.”
MMRGlobal Inc (OTCQB:MMRF) announced that the Au
As quoted in the press release:
The patent application was originally filed on September 14, 2007. The Australian NOA is significant to the Company in that it reinforces the value of the U.S. antibody patent that was announced by the Company on April 15th, 2013 and the similar antibody patent issued in Mexico in August 2012. These patents for the Company’s anti-CD20 monoclonal antibodies have particular utility in fighting cancers and are considered important assets of the Company based on benefits and commercial value demonstrated by Rituxan®, an anti-CD20 monoclonal antibody with reported sales of USD $7.285 billion in 2012, which is due to go off patent in 2015.
Click here to read the full MMRGlobal Inc (OTCQB:MMRF) press release.
